Literature DB >> 17580263

Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program.

Sergio Giralt1, Brent Logan, Douglas Rizzo, Mei-Jie Zhang, Karen Ballen, Christos Emmanouilides, Rajneesh Nath, Pablo Parker, David Porter, Brenda Sandmaier, Edmund K Waller, Juliet Barker, Steven Pavletic, Daniel Weisdorf.   

Abstract

To determine the long-term outcome of patients undergoing unrelated donor transplantation (URD) after a reduced intensity conditioning (RIC) regimen, we performed a retrospective analysis of the transplant outcomes of the first 5 years of RIC experience as reported to the National Marrow Donor Program (NMDP). Patients were included if they were older than 18 years and had undergone a URD transplant procured through the NMDP from January 1, 1996 until May 31, 2001, with an RIC regimen for a hematologic malignancy. The number of URDs performed using an RIC increased from 59 during 1996 to 1999, to 149 in the year 2000. RIC recipients were older (53 vs. 33 years) and had a higher likelihood of having advanced disease (81% vs. 51%) when compared to patients undergoing a myeloablative conditioning regimen during the same time period. The 5-year survival rate is 23% (95% confidence interval [CI]; 18, 28), whereas the 5 year incidence of progression/relapse is 43.4% (95% CI; 37,49). Prognostic factors for better overall survival on multivariate analysis were earlier disease stage, longer time to transplant from diagnosis, better HLA match, >or=90% performance score, and use of peripheral blood stem cells. This analysis demonstrates that long-term survival and disease control can be obtained with URD progenitor cell transplantation after RIC conditioning. However, only prospective trials will define the optimal role of this therapy in patients with hematologic malignancies. Therefore, URD transplantation with RIC should continue to be explored in the context of clinical trials.

Entities:  

Mesh:

Year:  2007        PMID: 17580263     DOI: 10.1016/j.bbmt.2007.03.011

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  31 in total

1.  Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

Authors:  Erica Warlick; Kwang Woo Ahn; Tanya L Pedersen; Andrew Artz; Marcos de Lima; Michael Pulsipher; Gorgun Akpek; Mahmoud Aljurf; Jean-Yves Cahn; Mitchell Cairo; Yi-Bin Chen; Brenda Cooper; Abhinav Deol; Sergio Giralt; Vikas Gupta; H Jean Khoury; Holbrook Kohrt; Hillard M Lazarus; Ian Lewis; Richard Olsson; Joseph Pidala; Bipin N Savani; Matthew Seftel; Gerard Socié; Martin Tallman; Celaettin Ustun; Ravi Vij; Lars Vindeløv; Daniel Weisdorf
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

2.  Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.

Authors:  Joseph Rosenthal; Jeffrey Wong; Anthony Stein; Dajun Qian; Debbie Hitt; Hossameldin Naeem; Andrew Dagis; Sandra H Thomas; Stephen Forman
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

Review 3.  Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Authors:  H J Symons; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-08-04       Impact factor: 5.483

4.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Authors:  Claudio G Brunstein; Ephraim J Fuchs; Shelly L Carter; Chatchada Karanes; Luciano J Costa; Juan Wu; Steven M Devine; John R Wingard; Omar S Aljitawi; Corey S Cutler; Madan H Jagasia; Karen K Ballen; Mary Eapen; Paul V O'Donnell
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

Review 5.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

Review 6.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

Review 7.  Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.

Authors:  Aravind Ramakrishnan; Brenda M Sandmaier
Journal:  Expert Rev Hematol       Date:  2010-02-01       Impact factor: 2.929

Review 8.  Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.

Authors:  Y Ofran; H M Lazarus; A P Rapoport; J M Rowe
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

9.  Intracellular disposition of fludarabine triphosphate in human natural killer cells.

Authors:  Erica L Woodahl; Joanne Wang; Shelly Heimfeld; Brenda M Sandmaier; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2008-09-10       Impact factor: 3.333

10.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Authors:  Rainer Storb; Boglarka Gyurkocza; Barry E Storer; Mohamed L Sorror; Karl Blume; Dietger Niederwieser; Thomas R Chauncey; Michael A Pulsipher; Finn B Petersen; Firoozeh Sahebi; Edward D Agura; Parameswaran Hari; Benedetto Bruno; Peter A McSweeney; Michael B Maris; Richard T Maziarz; Amelia A Langston; Wolfgang Bethge; Lars Vindeløv; Georg-Nikolaus Franke; Ginna G Laport; Andrew M Yeager; Kai Hübel; H Joachim Deeg; George E Georges; Mary E D Flowers; Paul J Martin; Marco Mielcarek; Ann E Woolfrey; David G Maloney; Brenda M Sandmaier
Journal:  J Clin Oncol       Date:  2013-03-11       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.